Clinical trials: Neurological Disorder
Obstructive Sleep Apnea
Clinical Evaluation of a Wearable Technology for the Diagnosis of Sleep Apnoea
This trial will aim to test a new wearable device for the diagnosis of Sleep Apnoea.
- Trial name
- NCT04028011
- Testing
- Novel Wearable device
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Acurable Ltd.
NMOSD, Neuromyelitis Optica Spectrum Disorders
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).
- Trial name
- ECU-NMO-304 (NCT06724809)
- Testing
- eculizumab
- Where
- 7 sites in China
- Volunteers
- 21 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Drug Resistant Epilepsy, Epilepsy, Drug Resistant
Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy
This study is to evaluate the safety and the intracranial electroencephalography (iEEG) changes of using NaviFUS System for the treatment of patients with drug resistant epilepsy.
- Conditions
- Drug Resistant Epilepsy, Epilepsy, Drug Resistant, Drug Refractory Epilepsy, Epilepsy, Drug Refractory
- Trial name
- NCT03860298
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Post-Stroke Spasticity, Cerebrovascular Accident
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
This is a study to confirm the superior efficacy of a single treatment of GSK1358820 over placebo in patients with post-stroke upper limb spasticity of both the wrist and finger flexors using the Modified Ashworth Scale (MAS)…
- Trial name
- NCT00460564
- Testing
- GSK1358820
- Where
- 18 sites in Japan
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Hearing Loss
Clinical Evaluation of the Nucleus 5 Cochlear Implant (CI) System
To evaluate the performance of the Nucleus 5 Cochlear Implant System.
- Trial name
- NCT01072409
- Testing
- Nucleus 5 Cochlear implant, Cochlear implantation
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Cochlear
Developmental Delay, Skeletal Abnormalities
Biomarker for Sly Disease (MPS VII) (BioSly)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)
- Conditions
- Developmental Delay, Skeletal Abnormalities, Hepatomegaly, Splenomegaly
- Trial name
- BioSly (NCT02298699)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Acute Low-back Pain, Chronic Low-back Pain
Impact of DuoTherm Compared to TENS on Pain and Disability With Acute and Chronic Low Back Pain
Evaluate pain and disability change in Low Back Pain with DuoTherm Compared to Active Control
- Conditions
- Acute Low-back Pain, Chronic Low-back Pain, Pain, Intractable
- Trial name
- NCT04494698
- Testing
- Duotherm VibraCool Back Device, TENS 8-channel unit
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- MMJ Labs LLC
Chronic Subdural Hematomas
PHIL™ Middle Meningeal Artery Embolization for First-Line Treatment of Chronic Subdural Hematoma IDE Trial
This is a prospective, randomized, controlled, open-label, blinded endpoint (PROBE) clinical investigation in which patients with non-emergent chronic subdural hematoma (cSDH) requiring treatment will be randomized (1:1) to…
- Trial name
- PHILFIRST (NCT07576998)
- Testing
- PHIL™ (Precipitating Hydrophobic Injectable Liquid), Surgical evacuation
- Volunteers
- 475 people
- Sponsor
- Microvention-Terumo, Inc.
Psychomotor Agitation, Schizophrenia
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.
- Conditions
- Psychomotor Agitation, Schizophrenia, Bipolar Disorder
- Trial name
- NCT04148963
- Testing
- Inhaled loxapine
- Volunteers
- 150 people
- Sponsor
- Lee's Pharmaceutical Limited
Ischemic Stroke
Study to Examine the Effects of MultiStem in Ischemic Stroke
A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke.
- Trial name
- NCT01436487
- Testing
- MultiStem
- Where
- 32 sites in United States, United Kingdom
- Volunteers
- 134 people
- Sponsor
- Healios K.K.
FSHD - Facioscapulohumeral Muscular Dystrophy
Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)
The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell product (ULSC) performs when treating Facioscapulohumeral Muscular Dystrophy (FSHD) 1 or 2.
- Trial name
- NCT07086521
- Testing
- ULSC
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Restem, LLC.
Duchenne Muscular Dystrophy
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
The primary objective of this study is to evaluate acute liver injury (ALI) rates associated with ELEVIDYS with the addition of sirolimus as an adjunct prophylactic immunosuppression agent.
- Trial name
- ENHANCE (NCT07542314)
- Testing
- ELEVIDYS, Sirolimus, Glucocorticoids
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sarepta Therapeutics, Inc.
Alzheimer's Disease
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.
- Trial name
- NCT00829816
- Testing
- Dimebon
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Medivation, Inc.
Charcot-Marie-Tooth Disease, Type 1A
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
The purpose of this study is to characterize the safety, tolerability, and pharmacokinetics of EDK060 as compared to placebo in adult patients with CMT1A.
- Trial name
- NCT07140614
- Testing
- EDK060, dose A, EDK060, dose B, EDK060, dose C
- Where
- 4 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, MCI
Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.
The purpose of this study is to establish multiple points of clinical validity for the Altoida digital biomarker assessment in individuals with a clinical diagnosis of cognitively normal (CN) and Mild Cognitive Impairment (MCI).
- Trial name
- NCT06223438
- Where
- United States
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Altoida
ALS - Amyotrophic Lateral Sclerosis
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded…
- Trial name
- CALM (NCT06649955)
- Testing
- Multi-site direct current stimulation (DCS)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- PathMaker Neurosystems Inc.
Alzheimer's Disease
Memantine - Communication Study
The study objective is to evaluate the effects of memantine treatment on communication abilities and other cognitive abilities in moderate to severe DAT patients.
- Trial name
- NCT00624026
- Testing
- Memantine-HCl
- Where
- Germany
- Volunteers
- 107 people
- Sponsor
- Merz Pharmaceuticals GmbH
Parkinson Disease, Parkinson's Disease
A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
- Trial name
- NCT07629115
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Innopeutics Corporation
Parkinson Disease, Early Parkinson's Disease
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease.
- Trial name
- NCT03329508
- Testing
- P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 544 people
- Sponsor
- Pharma Two B Ltd.
Alzheimer's Disease
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind…
- Trial name
- NCT02586909
- Testing
- RVT-101 35 mg tablets
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,099 people
- Sponsor
- Axovant Sciences Ltd.